Literature DB >> 7065534

Successful intermittent treatment of smear-positive pulmonary tuberculosis in six months: a cooperative study in Poland.

D E Snider, J Rogowski, M Zierski, E Bek, M W Long.   

Abstract

One hundred nineteen patients 15 to 70 yr of age, all with smear-positive, previously untreated, pulmonary tuberculosis, were treated with a 6-month regimen containing isoniazid and rifampin, supplemented during the initial 2 months with streptomycin and pyrazinamide. The 4 drugs were administered daily in the hospital during the initial 2 months, followed by isoniazid and rifampin administered twice weekly on an outpatient basis during the next 4 months. Adverse reactions to the drugs were seen in 19 patients, but only 6 had toxic reactions requiring withdrawal of drugs for 7 days or more. Three of the toxic reactions were attributed to streptomycin, 2 to rifampin, 1 to isoniazid, and none to pyrazinamide. Eighty-five (71%) of the 119 eligible patients completed treatment. After the first 2 months of therapy, 91% of these patients had negative sputum cultures, and all of them had negative cultures by the end of the third month of treatment. No relapses have occurred among the 84 patients observed for 18 months after therapy was completed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7065534     DOI: 10.1164/arrd.1982.125.2.265

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  14 in total

Review 1.  Tuberculosis: 9. Treatment.

Authors:  E Hershfield
Journal:  CMAJ       Date:  1999-08-24       Impact factor: 8.262

2.  Correlation between pyrazinamide activity and pncA mutations in Mycobacterium tuberculosis isolates in Taiwan.

Authors:  Tsi-Shu Huang; Susan Shin-Jung Lee; Hui-Zin Tu; Wen-Kuei Huang; Yao-Shen Chen; Chung-Kai Huang; Shue-Ren Wann; Hsi-Hsun Lin; Yung-Ching Liu
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

3.  Management of tuberculosis in urban homeless indigents.

Authors:  G Slutkin
Journal:  Public Health Rep       Date:  1986 Sep-Oct       Impact factor: 2.792

4.  Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs.

Authors:  Tawanda Gumbo; Chandima S W Siyambalapitiyage Dona; Claudia Meek; Richard Leff
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

5.  Survey of pulmonary tuberculosis in south and west Wales.

Authors:  H A Buechner
Journal:  Br Med J (Clin Res Ed)       Date:  1982-05-08

6.  Chemotherapeutic agents in pulmonary tuberculosis with special reference to isoniazid-ethambutol continuation therapy.

Authors:  A W Lees
Journal:  Ir J Med Sci       Date:  1985-05       Impact factor: 1.568

7.  Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis.

Authors:  G P Morlock; J T Crawford; W R Butler; S E Brim; D Sikes; G H Mazurek; C L Woodley; R C Cooksey
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

8.  Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis.

Authors:  A Scorpio; P Lindholm-Levy; L Heifets; R Gilman; S Siddiqi; M Cynamon; Y Zhang
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

9.  Does pyrazinoic acid as an active moiety of pyrazinamide have specific activity against Mycobacterium tuberculosis?

Authors:  L B Heifets; M A Flory; P J Lindholm-Levy
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

10.  Development and evaluation of a line probe assay for rapid identification of pncA mutations in pyrazinamide-resistant mycobacterium tuberculosis strains.

Authors:  Jun-Ichiro Sekiguchi; Tomohiko Nakamura; Tohru Miyoshi-Akiyama; Fumiko Kirikae; Intetsu Kobayashi; Ewa Augustynowicz-Kopec; Zofia Zwolska; Koji Morita; Toshinori Suetake; Hiroshi Yoshida; Seiya Kato; Toru Mori; Teruo Kirikae
Journal:  J Clin Microbiol       Date:  2007-06-27       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.